- Home
- MOS vs PCVX Comparison
MOS vs PCVX Comparison
Compare MOS & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MOS
- PCVX
- Stock Information
- Founded
- MOS 1987
- PCVX 2013
- Country
- MOS United States
- PCVX United States
- Employees
- MOS N/A
- PCVX N/A
- Industry
- MOS Agricultural Chemicals
- PCVX Biotechnology: Pharmaceutical Preparations
- Sector
- MOS Industrials
- PCVX Health Care
- Exchange
- MOS Nasdaq
- PCVX Nasdaq
- Market Cap
- MOS 10.4B
- PCVX 4.0B
- IPO Year
- MOS 2004
- PCVX 2020
- Fundamental
- Price
- MOS $34.22
- PCVX $31.86
- Analyst Decision
- MOS Buy
- PCVX Strong Buy
- Analyst Count
- MOS 12
- PCVX 8
- Target Price
- MOS $36.67
- PCVX $114.17
- AVG Volume (30 Days)
- MOS 4.0M
- PCVX 1.6M
- Earning Date
- MOS 11-11-2025
- PCVX 11-04-2025
- Dividend Yield
- MOS 2.58%
- PCVX N/A
- EPS Growth
- MOS 292.19
- PCVX N/A
- EPS
- MOS 2.95
- PCVX N/A
- Revenue
- MOS $11,253,400,000.00
- PCVX N/A
- Revenue This Year
- MOS $19.19
- PCVX N/A
- Revenue Next Year
- MOS N/A
- PCVX N/A
- P/E Ratio
- MOS $11.57
- PCVX N/A
- Revenue Growth
- MOS N/A
- PCVX N/A
- 52 Week Low
- MOS $22.36
- PCVX $27.66
- 52 Week High
- MOS $38.23
- PCVX $121.06
- Technical
- Relative Strength Index (RSI)
- MOS 56.84
- PCVX 48.08
- Support Level
- MOS $33.45
- PCVX $31.47
- Resistance Level
- MOS $34.51
- PCVX $33.16
- Average True Range (ATR)
- MOS 0.72
- PCVX 1.33
- MACD
- MOS 0.23
- PCVX 0.01
- Stochastic Oscillator
- MOS 83.00
- PCVX 39.70
About MOS Mosaic Company (The)
Mosaic is one of the largest phosphate and potash producers in the world. The company's assets include phosphate rock mines in Florida, Brazil, and Peru and potash mines in Saskatchewan, New Mexico, and Brazil. Mosaic also runs a large fertilizer distribution operation in Brazil through its Mosaic Fertilizantes business.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.